Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan.

(see supplementary appendix Table S2 of [ 18 ]) [ 18 ] reported adjusted HRs (based on a Cox regression model including treatment group and the respective baseline characteristics), where stratifying for AFP was the only variable to produce a nominally significant OS HR (0.856, CI 0.736–0.995).

also in 7,732 other papers